FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
Wednesday, September 17th, 2014 – Fenway Park, Boston, MA The Redefining Early Stage Investments (RESI) Conference is reinventing the way investors and entrepreneurs connect and share...
LIFE SCIENCES VENTURE CAPITAL INVESTMENTS SOAR IN Q2 TO HIGHEST LEVEL SINCE 2007, ACCORDING TO THE MONEYTREE REPORT
Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay
Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications
Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
-- Roche to acquire InterMune for $74.00 per share --
BASEL, Switzerland, Aug.